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Greater Trochanteric Pain Syndrome
Percutaneous Tendon Fenestration Versus Platelet-Rich
Plasma Injection for Treatment of Gluteal Tendinosis
reater trochanteric pain syndrome is a common condition
that most commonly affects middle-aged and elderly women
and potentially younger active male and female individuals.1
Symptoms include pain referable to the lateral hip as well as point
tenderness that often interferes with activity and sleeping.2,3
Contrary to prior misconceptions that symptoms were due to under-
lying bursitis, it has been shown that the underlying etiology for
greater trochanteric pain syndrome is most commonly tendinosis 
or a tendon tear of the gluteus medius, gluteus minimus, or both at
the greater trochanter and that tendon inflammation (or tendinitis)
is not a major feature.4–7 In addition, adjacent bursal distention is
uncommon, and the bursa is neither inflamed nor a cause of patient
symptoms in most situations.7,8 Treatment of greater trochanteric
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Objectives—The purpose of this study was to compare ultrasound-guided percuta-
neous tendon fenestration to platelet-rich plasma (PRP) injection for treatment of
greater trochanteric pain syndrome.
Methods—After Institutional Review Board approval was obtained, patients with symp-
toms of greater trochanteric pain syndrome and ultrasound findings of gluteal tendi-
nosis or a partial tear (<50% depth) were blinded and treated with ultrasound-guided
fenestration or autologous PRP injection of the abnormal tendon. Pain scores were
recorded at baseline, week 1, and week 2 after treatment. Retrospective clinic record
review assessed patient symptoms. 
Results—The study group consisted of 30 patients (24 female), of whom 50% were
treated with fenestration and 50% were treated with PRP. The gluteus medius was
treated in 73% and 67% in the fenestration and PRP groups, respectively. Tendinosis
was present in all patients. In the fenestration group, mean pain scores were 32.4 at base-
line, 16.8 at time point 1, and 15.2 at time point 2. In the PRP group, mean pain scores
were 31.4 at baseline, 25.5 at time point 1, and 19.4 at time point 2. Retrospective
follow-up showed significant pain score improvement from baseline to time points 1 and
2 (P < .0001) but no difference between treatment groups (P = .1623). There was 71%
and 79% improvement at 92 days (mean) in the fenestration and PRP groups, respec-
tively, with no significant difference between the treatments (P >.99).
Conclusions—Our study shows that both ultrasound-guided tendon fenestration and
PRP injection are effective for treatment of gluteal tendinosis, showing symptom
improvement in both treatment groups.
Key Words—fenestration; gluteal; musculoskeletal ultrasound; platelet-rich plasma;
tendinosis; tenotomy; trochanter
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pain syndrome should therefore be directed to treatment
of the underlying tendon condition.
Ultrasound-guided percutaneous needle fenestration
(or tenotomy) has been used to effectively treat underly-
ing tendinosis and tendon tears, including tendons about
the hip and pelvis.9–13 The rationale behind tendon fenes-
tration is that a chronic degenerative tendon process is
converted to an acute process, and inherent growth factors
are introduced with bleeding, thereby promoting tendon
healing.10 Similarly, autologous platelet-rich plasma
(PRP), often combined with tendon fenestration, has been
used throughout the body to treat tendinosis and tendon
tears, as injection into a tendon promotes healing via the
introduction of growth factors concentrated in and released
from platelets.14 Although studies have shown patient
improvement with PRP treatment, the true effectiveness
of this treatment compared to other treatments remains
uncertain.15–17
Although percutaneous ultrasound-guided tendon
fenestration has been shown to be effective about the hip
and pelvis, there are no data describing the use of PRP
for treatment of gluteal tendons, and there is no study com-
paring the effectiveness of each treatment for gluteal
tendinopathy.9 The purpose of this blinded prospective
clinical trial was to compare ultrasound-guided tendon
fenestration and PRP for treatment of gluteus tendinosis or
partial-thickness tears in greater trochanteric pain syndrome.
Materials and Methods
Institutional Review Board approval was obtained before
initiation of this study. Patients were recruited from refer-
ring physicians of various departments, including internal
medicine, family medicine, rheumatology, sports medicine,
physical medicine and rehabilitation, and orthopedic surgery.
If a patient had signs and symptoms consistent with the
clinical diagnosis of greater trochanteric pain syndrome,
which included pain referable to the greater trochanter,
and had failed conservative management, including phys-
ical therapy and nonsteroidal anti-inflammatory drugs,
the patient would be considered for the clinical trial. If the
patient was interested in enrolling, the patient would then
be referred for an ultrasound examination to evaluate for a
gluteal tendon abnormality and to exclude other types of
hip disorders as part of patient care.
Ultrasound examinations of the hip were performed
by 1 of 10 fellowship-trained musculoskeletal radiologists
with musculoskeletal ultrasound experience using com-
mercially available ultrasound equipment (iU22 and EPIQ;
Philips Healthcare, Bothell, WA; and LOGIQ 9 and E9;
GE Healthcare, Milwaukee, WI) and transducers (linear
and curvilinear transducers with variable frequencies rang-
ing from 5 to 15 MHz). The hip ultrasound protocol
included imaging the gluteus minimus and medius tendons
in short and long axes, as well as imaging the greater
trochanteric area for the presence of bursal distention.
Tendinosis was characterized as abnormal hypoecho -
genicity of the tendon with possible enlargement. A tendon
tear was characterized as an anechoic tendon defect. In con-
trast to a partial-thickness tear, a full-thickness tear shows
an anechoic defect extending to both tendon surfaces with
possible tendon retraction.
The principal investigator reviewed the sonograms 
of the potential participant. Initial inclusion criteria
included the presence of tendinosis or a partial-thickness
tendon tear (<50% depth) of the gluteus minimus or glu-
teus medius tendon. If inclusion criteria were met, the pri-
mary investigator then contacted the potential participant
via phone to explain the study and to assess for exclusion
criteria, which included age younger than 18 years, preg-
nancy, risk of bleeding due to anticoagulant medication,
presence of malignancy, and steroid injection less than 3
months before enrollment. Patients were then informed to
discontinue aspirin and other nonsteroidal anti-inflamma-
tory drugs for 2 weeks before the procedure.
At the time of the procedure, the patient signed the
Institutional Review Board–approved research consent form.
The patient was informed of the procedure risks (bleed-
ing, infection, tendon rupture, allergy to medication, and
pain), and the procedure consent form was also signed by
the patient and primary investigator. An ultrasound exam-
ination of the affected hip was performed to document 
the presence of gluteus minimus or medius tendinosis or a
partial-thickness tear (<50% depth), and the skin was
marked at the planned puncture site. If both tendons were
abnormal, the most sonographically abnormal tendon that
was also symptomatic with transducer pressure was cho-
sen for treatment. The patient also answered a series of
questions with regard to hip symptoms (Table 1).
Patients were placed into either the tendon fenestra-
tion or PRP treatment arm based on the previous patient’s
treatment so that fenestration and PRP treatments would
alternate between each subsequent patient. If there was an
error in the PRP process (inadequate venous blood draw
or failed PRP preparation), then that patient would be con-
verted to the fenestration treatment arm. Patients were
blinded with respect to their treatment arm.
In each patient, venous blood was drawn from one of
the antecubital veins at the elbow. If the patient was in the
tendon fenestration arm, 10 mL of venous blood was
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drawn and discretely discarded, although the centrifuge lid
was opened and closed regardless. If in the PRP treatment
arm, 60 mL of blood was drawn into a syringe with the anti-
coagulant citrate dextrose, placed into a centrifuge (Harvest
Technologies, Lakewood, CO), and centrifuged at up to
2650 rpm for approximately 14 minutes. This PRP prepa-
ration kit is commercially available and is reported to
produce a leukocyte-rich sample (primarily mononuclear)
with a platelet concentration 4 to 6 times that in whole
blood. A successful PRP preparation resulted in approxi-
mately 10 mL of PRP. If the PRP sample was less than 7 mL,
the sample was discretely discarded, and the patient was
switched to the tendon fenestration arm.
For the ultrasound-guided percutaneous procedure,
the transducer (linear or curvilinear, >7 MHz) was positioned
either long or short axis to the involved gluteal tendon.
With a sterile technique, a transducer cover, and sterile
drapes, a 20-gauge, 3.5-in spinal needle with trocar was
inserted in plane with the ultrasound transducer and sound
beam. Less than 1 mL of local anesthetic (1% lidocaine)
was initially injected with a 25-gauge needle at the skin
surface. Subsequently, less than 1 mL of lidocaine was then
injected over the surface of the tendon via the 20-gauge
spinal needle. In the tendon fenestration arm, the 20-
gauge needle with trocar removed was passed approxi-
mately 20 to 30 times at various angles through the
abnormal tendon until the abnormal area was covered and
the tendon softened (Figure 1). In the PRP treatment arm,
the needle was inserted into the deepest aspect of the ten-
J Ultrasound Med 2016; 35:2413–2420 2415
Jacobson et al—Fenestration Versus Plasma Injection for Greater Trochanteric Pain Syndrome
Figure 1. Images from a 55-year-old man with gluteus minimus tendi-
nosis treated with fenestration. A and B, Sonograms short axis (A) and
long axis (B) to the gluteus minimus showing a hypoechoic and thick-
ened gluteus minimus tendon (arrows). Note the apex of the greater
trochanter (asterisk) separating the anterior facet (AF) and lateral facet
(LF) seen short axis to the femur in A, gluteus medius (Gmed), and ili-
otibial tract (ITB). C, Sonogram long axis to the gluteus minimus show-
ing a 20-gauge spinal needle (arrowheads) with the distal tip in the area
of tendinosis (arrow). Right side of A is anterior, and right side of B and
C is distal.
Table 1. Patient-Reported Outcomes
Outcome Score
Level of pain 0 (no pain) to 10 (pain as bad as 
could imagine)
Pain interfering with 0 (does not interfere) to 10 
general activity (completely interferes)
Pain interfering with walking 0 (does not interfere) to 10 
(completely interferes)
Pain interfering with 0 (does not interfere) to 10
climbing stairs (completely interferes)
Pain interfering with sleeping 0 (does not interfere) to 10 
(completely interferes)
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don abnormality, and the PRP was injected as the needle
was withdrawn through the abnormal tendon segment
(Figures 2 and 3). This process was repeated until the
entire abnormal tendon segment was treated. In contrast to
the tendon fenestration arm, the number of times the nee-
dle was passed through the tendon was minimized and esti-
mated as less than 10. During the procedure, the patient
was instructed to look away from the procedure area to
remain blinded to the treatment arm.
After the procedure, the patient was instructed to
avoid nonsteroidal anti-inflammatory drugs for 2 weeks.
For the first week, the patient was also instructed to avoid
strenuous activity with regard to the hip. Activity was grad-
ually increased during the second week as tolerated.
Patients were contacted via phone or e-mail by the primary
investigator at weeks 1 and 2 to assess hip symptoms by
asking the same series of questions that was completed
before the procedure (Table 1). The patient was instructed
to follow-up with the referring clinician to reassess the hip
between 4 and 6 weeks. Patients were subsequently e-
mailed, and clinical records were reviewed by the primary
investigator to determine whether patient symptoms refer-
able to the greater trochanter were improved, similar, or
worse compared to before the procedure beyond the ini-
tial 2-week data collection.
Baseline patient demographics and summated pain
scores were compared between the treatment groups
(fenestration versus PRP) to determine whether any
significant difference existed, using the Fisher exact test 
for categorical variables and an independent-group t test
for continuous variables. Summated patient pain scores
were analyzed by repeated-measures 1-way analysis of vari-
ance over time adjusted for the treatment group. A paired
comparison of different time points was performed by post
hoc Tukey correction for multiple comparisons. In addi-
tion, the percentages of patients who showed improve-
ment over time based on retrospective clinical chart review
were compared between the treatment arms for any sig-
nificant difference by the Fisher exact test. P < .05 was con-
sidered statistically significant.
Results
Of the 30 patients, 50% were treated with tendon fenes-
tration (Figure 1), and 50% were treated with PRP (Fig-
ures 2 and 3). The mean patient age was 57 years (range, 24
to 81 years), with no significant age difference between the
treatment groups (Table 2). The patients consisted of 6 men
and 24 women, with no significant difference between the
treatment groups. The left side was affected in 12 patients
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Figure 2. Images from a 69-year-old woman with gluteus medius tendi-
nosis treated with PRP injection. A and B, Sonograms short axis (A) and
long axis (B) to the gluteus medius showing a hypoechoic and thick-
ened gluteus medius tendon (arrows) at the attachment on the lateral
facet (LF) and superoposterior facet (SPF) of the greater trochanter.
Note the apex of the greater trochanter (asterisk) separating the ante-
rior facet (AF) and lateral facet seen short axis to the femur in A, gluteus
minimus (Gmin), and iliotibial tract (ITB). C, Sonogram long axis to the
gluteus medius showing a 20-gauge spinal needle (arrowheads) with
the distal tip in the area of tendinosis (arrow). Right side of A is anterior,
and right side of B and C is distal.
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and the right side in 18, with no significant difference between
the treatment groups. The gluteus medius was treated in
73% and 67% in the fenestration and PRP groups, respec-
tively, with no significant difference between the treatment
groups, with the gluteus minimus treated in the remaining
patients. Tendinosis was present in all patients, with no
patients having a tendon tear. In no patient was a dis-
tended bursa identified in the region of the greater
trochanter, and similarly, in no cases were tendon calcifi-
cations seen at the ultrasound examination. Two
patients initially assigned to the PRP group were moved to
the fenestration group because of an error in the PRP
preparation process. There were no immediate complica-
tions after the procedures.
Regarding follow-up intervals after tendon proce-
dures, the mean time from the procedure to symptom
assessment at time point 1 in the fenestration group was
7.9 (range, 7 to 13) days, and in the PRP group, it was 8.0
(range, 7 to 10) days, with no significant difference between
the groups (P = .8996). At time point 2, the mean time
from the procedure to symptom assessment in the fenes-
tration group was 17.6 (range, 14 to 23) days, and in the
PRP group, it was 15.3 (range, 14 to 20) days, which was
significantly different between the groups (P = .0425).
Retrospective clinical follow-up was available in 93% (14 of
15) and 93% (14 of 15) of the fenestration and PRP treat-
ment groups, respectively, with mean intervals of 128
(SD, 141.1; range, 15 to 555) and 55.7 (SD, 27.7; range,
21 to 108) days from baseline, respectively (mean for both
groups combined was 92 days), with no significant differ-
ence between the treatment groups (P = .0815).
When comparing the pain scores between the treat-
ment groups at each time point, at baseline the mean pain
score in the fenestration group was 32.4 (SD, 10.2; range, 8
to 49), and in the PRP group, it was 31.4 (SD, 7.3; range, 11
to 41). At time point 1, the mean pain score after fenestra-
tion was 16.8 (SD, 11.46; range, 0 to 34), which was lower
than the PRP group pain score of 25.5 (SD, 8.77; range, 9
to 40.5). At time point 2, the mean pain score after fenes-
tration was 15.2 (SD, 10.8; range, 0 to 34), and after PRP
treatment, it was 19.4 (SD, 10.26; range, 4 to 42).
Regarding changes in summated pain scores in each
treatment group from baseline, at time point 1, 93% of
patients (13 of 14) after fenestration showed improvement
(mean improvement, 15; range, 46 to –4), compared with
79% (11 of 14) after PRP treatment (mean improvement,
5.6; range, 21 to –15). At time point 2 compared to base-
line, 93% of patients (14 of 15) after fenestration showed
improvement (mean improvement, 17; range, 46 to 0),
compared with 80% (12 of 15) after PRP treatment (mean
improvement, 12; range, 28 to –5).
Analysis of summated pain scores showed that overall,
there was a significant time effect on the summated pain
score (Table 3). The type of treatment had no significant
effect on the summated pain score. Pair-wise comparison
showed a significant change in summated pain scores
between baseline and time point 1, as well as baseline and
time point 2. There was no significant change in summated
pain scores between time points 1 and 2. At final retrospec-
tive clinical follow-up, 71% (10 of 14) of fenestration patients
and 79% (11 of 14) of PRP patients showed improvement,
with no significant difference between the groups (P > .99).
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Figure 3. Images from a 61-year-old woman with gluteus medius tendinosis treated with PRP injection. A, Sonogram long axis to the gluteus medius
showing hypoechoic tendinosis (arrows) of the gluteus medius tendon predominantly at the attachment on the superoposterior facet (SPF) with less
involvement at the lateral facet (LF) and the greater trochanter. B, Sonogram long axis to the gluteus medius showing a 20-gauge spinal needle
(arrowheads) with the distal tip in the area of tendinosis (arrow). Right side of images is distal.
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Discussion
Symptoms from greater trochanteric pain syndrome can
be quite substantial and markedly decrease quality of life.
The underlying conditions producing such symptoms in
most cases are tendinosis and tears of the gluteal tendons
at the greater trochanter.5–7 An effective percutaneous
treatment directed at these conditions would therefore be
important. Our study has shown that both ultrasound-
guided tendon fenestration and PRP injection are effective
for treatment of greater trochanteric pain syndrome sec-
ondary to tendinosis, with improvement in pain scores
from baseline to weeks 1 and 2 and 71% and 79% improve-
ment at 92 days (mean) in the fenestration and PRP groups,
respectively, with no significant difference between the
treatments.
The greater trochanter of the proximal femur serves
as the insertion of gluteus minimus and medius tendons.
The footprints or bony insertions of the gluteus minimus
and medius tendons on the greater trochanter are geograph-
ically related to the facets of the greater trochanter, where
the gluteus minimus tendon inserts onto the anterior facet,
and the gluteus medius inserts onto the lateral and supero-
 posterior facets.18 The gluteus maximus passes superficial
to the posterior facet to insert onto the linea aspera of the
proximal femur and iliotibial band. Respective bursae are
located deep to each gluteal muscle and tendons.
Greater trochanteric pain syndrome most commonly
involves middle-aged and elderly women. Pain is character-
istically referred to the lateral hip over the greater trochanter
with point tenderness. Symptoms are exacerbated by walk-
ing; pain interfering with sleeping often occurs when
patients lie on the lateral affected hip.2 The underlying con-
dition in the setting of greater trochanteric pain syndrome
in most cases has been shown to be tendinosis or a tendon
tear of the gluteus medius and, less commonly, the gluteus
minimus tendon, with an absence of acute inflammation.4–6
Bursitis is not a common cause of symptoms. In patients
with greater trochanteric pain syndrome, only 20% will
have a distended trochanteric bursa on ultrasound imag-
ing.7 In addition, it has been shown that a distended bursa
in this setting is typically not inflamed.8 The distended
bursa is not believed to be the primary cause of symptoms
but may be simply a finding associated with the underlying
gluteal tendon abnormality. Treatment for trochanteric
pain syndrome should therefore be directed to treatment
of the underlying tendon disorder.
A historic treatment for greater trochanteric pain syn-
drome has been percutaneous corticosteroid injection,
largely because of the misconception that inflammation
was present. The use of corticosteroids in this setting is
counterintuitive, as true tendinitis is not present, and true
bursitis is uncommon. When corticosteroids are injected
superficial to tendinosis, pain levels have been shown to
improve, with one study reporting that 72% of patients
were improved 1 month after injection.1 However, the pain
relief is typically short lived, and there is a risk of tendon
rupture if corticosteroids are injected into a tendon.10
Percutaneous tendon fenestration (also called dry
needling or tenotomy) has been used to directly treat
tendinosis and partial-thickness tendon tears.1 The theory
behind this treatment is that a chronic degenerative process
is converted to an acute process. Bleeding introduces growth
factors to induce inflammation and promote healing.
The use of ultrasound guidance is important for accurately
directing the tendon treatment to the abnormal area.
Although studies have shown patient improvement after
ultrasound-guided tendon fenestration, there are only lim-
ited studies evaluating fenestration of gluteal tendons, and
Table 2. Patient Demographics







Side, n (%) .2635
Left 8 (53.33) 4 (26.67)
Right 7 (46.67) 11 (73.33)
Sex, n (%) .1686
Female 10 (66.67) 14 (93.33)
Male 5 (33.33) 1 (6.67)
Tendon, n (%) >.99
Gluteus minimus 4 (26.67) 5 (33.33)
Gluteus medius 11 (73.33) 10 (66.67)
Table 3. Repeated Measures of Analysis of Pain Score Total Over Time
Adjusted for Treatment Type
Mean Pain 
Parameter Score Estimate (SE) Pa
Visit <.0001
Treatment 25.42 (1.91) vs 21.56 (1.91) 0.1623
Pair-wise comparison for visits
Time point 1 vs baseline (n = 28) 21.27 (1.87) vs 31.92 (1.82) <.0001
Time point 2 vs baseline (n = 30) 17.28 (1.82) vs 31.92 (1.82) <.0001
Time point 2 vs 1 (n = 28) 17.28 (1.82) vs 21.27 (1.87) .0569
aOne-way repeated measures analysis of variance for outcome of total
pain score over time adjusted for treatment with post hoc Tukey correc-
tion to adjust for multiple comparisons.
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there are no studies comparing gluteal tendon fenestration
to other tendon treatments such as PRP injection.9–13,19–21
Although a comprehensive review of PRP treatment is
beyond the scope of this discussion and has previously
been described in the literature, PRP involves centrifuging
autologous venous blood to separate the platelet-rich layer,
which can then be injected into an abnormal tendon to
promote healing.14,22,23 Similar to tendon fenestration but
in a higher concentration, growth factors are released
from α granules in platelets to promote tendon healing.
When PRP is injected, the tendon is typically fenestrated as
well, and the use of ultrasound guidance ensures accurate
localization of the tendon abnormality and targeted injection.
There are intrinsic variations in PRP preparations with regard
to platelet count and whether PRP preparations are leuko-
cyte rich or leukocyte poor depending on which prepara-
tion kit is used. Nonetheless, studies have shown that patients
improve after PRP tendon injection. However, most meta-
analyses are inconclusive with regard to the effectiveness of
PRP compared to other percutaneous tendon treatments,
such as fenestration.15,16
The results of our study show that both ultrasound-
guided percutaneous tendon fenestration and PRP
injection are effective for treatment of gluteus medius and
minimus tendinosis. In 2-week follow-up of patients,
improvement in pain scores was seen in 93% (14 of 15) in
the fenestration group and 80% (12 of 15) in the PRP group.
The lower improvement rate in the PRP group at this time
may be explained by the inflammation induced by the PRP
injection, which in this study was leukocyte rich; however,
there was a significant improvement in summated pain
scores between baseline and time points 1 and 2 but no
significant difference in pain scores between the treatment
types. Subsequent retrospective assessment of symptoms
at 92 days after the procedures showed improvement in
71% and 79% of patients in the fenestration and PRP groups,
respectively, with no significant difference between the
treatments. This finding was also consistent with PRP
results from the literature at different tendon injection sites,
where symptom improvement continues over time. These
results show that the symptom improvement is present
early after treatment and is sustained over time.
With regard to the PRP procedure, in this study, the
tendon fenestration component was intentionally mini-
mized compared to the dedicated tendon fenestration treat-
ment group. In clinical practice, tendon fenestration is
commonly performed either before or during the autologous
PRP injection. It is not known whether increasing the fen-
estration component of the procedure would have any
effect on patient symptom outcomes after PRP treatment.
There were a number of study limitations that need
to be addressed. First, long-term symptom improvement
was limited by retrospective assessment, with a somewhat
short interval and a wide range of follow-up durations.
The sample size was limited because of budgetary con-
straints, and it remains possible that the effect size was not
large enough to detect a difference between the treatment
groups. Nonetheless, the results do show symptom improve-
ment in the short term and months after treatment.
The limited retrospective follow-up could be interpreted as
a potential positive outcome if asymptomatic patients did
not seek further treatment for their greater trochanter
symptoms. Another limitation was that the PRP samples
were not individually assessed for platelet count; however,
the PRP preparation kit used is commercially available and
is reported to concentrate platelets to 4 to 6 times that in
whole blood. An additional limitation was that all patients
had tendinosis, so it is unclear whether patients with tendon
tears would respond in a different manner. One last limi-
tation was that patient care after treatment was not con-
trolled, which may affect longer-term clinical outcomes.
Future prospective studies to include more long-term and
objective clinical assessment are required.
In conclusion, this single-blinded prospective study
shows that both ultrasound-guided tendon fenestration
and PRP injection are effective for treatment of greater
trochanteric pain syndrome, showing improvement in pain
scores at 1 and 2 weeks, with no significant difference
between the treatments. Improvement was also seen at
92 days (mean) in 71% and 79% of the fenestration and
PRP groups, respectively. Future randomized controlled
trials are needed to determine more long-term clinical
outcomes.
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